文献速递先天性心脏病外科瓣膜外科

20年期间外科与经皮肺动脉瓣植入的对比分析

Comparative analysis of surgical and percutaneous pulmonary valve implants over a 20-year period.
PubMed 文献 · Eur J Cardiothorac Surg · 2022-01-01

结果显示两组5年生存率分别为92%和96.8%,10年分别为85.8%和95.1%;Melody PPVI的感染性心内膜炎年化发生率显著更高(0.024 vs 0.0024/人年,P<0.05)。PVR长期随访显示半数患者将在术后10-15年需再次置换。

要点

  • PPVI适应证从生物瓣 conduit 内狭窄扩展至自体右室流出道。
  • PPVI与PVR中期生存相似,但Melody PPVI感染性心内膜炎风险显著更高。
  • 首次瓣膜植入时应考虑终身再瓣膜化策略。

核心结论

  • 越来越多的需肺动脉瓣置换患者可经皮治疗,但应制定终身再瓣膜化策略。

主要发现

  • PVR最常见适应证为自体肺动脉瓣反流,PPVI更常用于既往生物瓣或 conduit 的肺动脉狭窄。
  • 5年生存率PPVI 92%、PVR 96.8%;10年生存率PPVI 85.8%、PVR 95.1%。
  • 术前NYHA心功能III和IV级是不良结局的最重要预测因素。
  • Melody PPVI的感染性心内膜炎年化发生率为0.024/人年,显著高于PVR的0.0024/人年(P<0.05)。
  • PVR长期随访显示半数患者将在术后10-15年需再次置换。

临床怎么用

  • 对于需肺动脉瓣置换的患者,可考虑经皮途径,但应关注Melody PPVI的感染性心内膜炎风险。
  • 首次瓣膜植入时应规划终身再瓣膜化策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Since percutaneous pulmonary valve implantation (PPVI) was introduced to prolong the lifetime of surgically placed right ventricular to pulmonary artery conduits, valve technology has evolved and the indications for PPVI expanded to native and larger right ventricular outflow tracts. We explore how indications, patient populations and outcomes compare to surgical pulmonary valve replacement (PVR). METHODS: This is a retrospective cohort study of PPVI and PVR procedures between 1998 and 2020 at a single UK centre. One hundred and twenty-eight patients underwent PPVI and 365 patients PVR. Primary outcome measures were survival, infective endocarditis and reintervention. RESULTS: The most common indication for PVR was replacement of the native pulmonary valve for pulmonary regurgitation whereas PPVI was more commonly used to treat pulmonary stenosis in a previously placed bioprosthetic conduit or valve. Treatment indications for PPVI expanded over the study to include the native right ventricular outflow tract. Survival was similar for PPVI and PVR (92% PPVI and 96.8% PVR at 5 years; 85.8% PPVI and 95.1% PVR at 10 years). Preprocedural New York Heart Association class 3 and 4 was the most important predictor of poor outcome. Annualized infective endocarditis rate was significantly higher for the Melody PPVI (0.024 vs 0.0024/person/year for PVR, P < 0.05). Both groups showed significant symptomatic improvement postprocedure with remodelling of ventricular volumes and improvement in cardiac output. Long-term follow-up for PVR showed half of patients will need replacement at 10-15 years post-index procedure. CONCLUSIONS: An increasing number of patients requiring PVR can now be treated percutaneously. A lifetime strategy for re-valving should be considered at the first valve implant.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Hribernik I, Thomson J, Ho A, et al. Comparative analysis of surgical and percutaneous pulmonary valve implants over a 20-year period. Eur J Cardiothorac Surg. 2022. PMID: 34406369. doi:10.1093/ejcts/ezab368

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。